Health2 months ago
Milestone Pharmaceuticals Downgraded to ‘Sell’ Amid Challenges
Milestone Pharmaceuticals has been downgraded to a ‘Sell’ rating by analysts, primarily due to concerns regarding the market viability of its product, CARDAMYST. This intranasal treatment...